We synthesise tumour-intrinsic and extrinsic neurotrophic axes, delineate neuro-immune crosstalk, and highlight interventions—TRK/RET inhibitors, CSF1R blockade, β-adrenergic antagonists—aimed at converting this liability into therapeutic leverage. This evidence concerns the gene CSF1R and neoplasm.